241 related articles for article (PubMed ID: 37824027)
1. Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin.
MacIsaac RJ; Deed G; D'Emden M; Ekinci EI; Hocking S; Sumithran P; Rasalam R
Diabetes Ther; 2023 Dec; 14(12):1997-2014. PubMed ID: 37824027
[TBL] [Abstract][Full Text] [Related]
2. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials.
Min T; Bain SC
Diabetes Ther; 2021 Jan; 12(1):143-157. PubMed ID: 33325008
[TBL] [Abstract][Full Text] [Related]
3. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
Nauck MA; D'Alessio DA
Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
[TBL] [Abstract][Full Text] [Related]
4. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
Urva S; Levine JA; Schneck K; Tang CC
Curr Med Res Opin; 2024 Apr; 40(4):567-574. PubMed ID: 38407177
[TBL] [Abstract][Full Text] [Related]
5. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
Frías JP
Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356
[TBL] [Abstract][Full Text] [Related]
6. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity.
Gallwitz B
Front Endocrinol (Lausanne); 2022; 13():1004044. PubMed ID: 36313764
[TBL] [Abstract][Full Text] [Related]
7. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
Lingvay I; Cheng AY; Levine JA; Gomez-Valderas E; Allen SE; Ranta K; Torcello-Gómez A; Thieu VT
Diabetes Obes Metab; 2023 Apr; 25(4):965-974. PubMed ID: 36514843
[TBL] [Abstract][Full Text] [Related]
8. The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects.
Jensen TL; Brønden A; Karstoft K; Sonne DP; Christensen MB
Patient Prefer Adherence; 2024; 18():373-382. PubMed ID: 38352159
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data.
Goldenberg RM; Teoh H; Verma S
Curr Opin Cardiol; 2023 Nov; 38(6):539-545. PubMed ID: 37792556
[TBL] [Abstract][Full Text] [Related]
10. Tirzepatide: Clinical review of the "twincretin" injectable.
Krauss Z; Hintz A; Fisk R
Am J Health Syst Pharm; 2023 Jul; 80(14):879-888. PubMed ID: 37070418
[TBL] [Abstract][Full Text] [Related]
11. An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program.
Frías JP
Expert Rev Endocrinol Metab; 2023 Mar; 18(2):111-130. PubMed ID: 36908082
[TBL] [Abstract][Full Text] [Related]
12. Tirzepatide: A Review in Type 2 Diabetes.
France NL; Syed YY
Drugs; 2024 Feb; 84(2):227-238. PubMed ID: 38388874
[TBL] [Abstract][Full Text] [Related]
13. The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist.
Cho YK; La Lee Y; Jung CH
J Lipid Atheroscler; 2023 Sep; 12(3):213-222. PubMed ID: 37800107
[TBL] [Abstract][Full Text] [Related]
14. Tirzepatide for type 2 diabetes.
Anderson SL; Marrs JC
Drugs Context; 2023; 12():. PubMed ID: 37664792
[TBL] [Abstract][Full Text] [Related]
15. Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review.
Liarakos AL; Koliaki C
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509514
[TBL] [Abstract][Full Text] [Related]
16. Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes.
Kaneko S
touchREV Endocrinol; 2022 Jun; 18(1):10-19. PubMed ID: 35949358
[TBL] [Abstract][Full Text] [Related]
17. Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide.
Boye KS; Sapin H; Dong W; Williamson S; Lee CJ; Thieu VT
Diabetes Ther; 2023 Nov; 14(11):1867-1887. PubMed ID: 37668888
[TBL] [Abstract][Full Text] [Related]
18. Perspectives on weight control in diabetes - Tirzepatide.
Várkonyi TT; Pósa A; Pávó N; Pavo I
Diabetes Res Clin Pract; 2023 Aug; 202():110770. PubMed ID: 37279858
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
[TBL] [Abstract][Full Text] [Related]
20. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
